Pfizer Inc. (PFE)
Is Pfizer Stock A Buy Or A Sell With Covid-Era Growth In The Rearview?
Is Pfizer stock a buy or a sell as sales of its Covid products continue diving? Is PFE stock a buy or a sell right now?
How Should You Play Pfizer (PFE) After COVID-Flu Shot Setback?
After Pfizer's (PFE) better-than-expected second-quarter results and the bullish outlook for the year, investors who own Pfizer's stock may consider staying invested.
2 Cheap Passive Income Stocks to Buy Now
Social Security faces potential benefit reductions after 2035. Dividend-paying stocks can form a solid basis for a passive income portfolio.
Pfizer (PFE), BioNTech COVID-Flu Combo Shot Study Falters
Pfizer's (PFE) COVID and flu combination vaccine demonstrates a continued trend of higher responses against influenza A but fails to show non-inferiority against the influenza B strain.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Pfizer Is Staking Its Turnaround on Cancer Drugs
BOTHELL, Wash.—At a recent company town hall here, Pfizer's cancer-business chief looked over some 100 scientists, marketers and other staffers who had just joined the giant drugmaker through a $43 billion acquisition and asked them to reach below their chairs.
Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?
Pfizer and BioNTech recently reported top-line results from a trial of its combination vaccine that was meant to protect against the flu and COVID-19. The partners' combination shot failed to achieve non-inferiority when compared to an approved flu vaccine.
Is Pfizer Stock Ready to Bounce Back?
Pfizer's revenue grew on a year-over-year basis for the first time in a while. Though a recent acquisition helped, there were other factors that contributed.
Why Pfizer Stock Slumped on Friday
Its combination COVID-19/influenza vaccine fell short of one of its endpoints in a late-stage clinical trial. The U.S. pharmaceutical giant is developing the jab with its European partner BioNTech.
Pfizer Dividend Yield Pushes Past 6%
In trading on Friday, shares of Pfizer were yielding above the 6% mark based on its quarterly dividend (annualized to $1.68), with the stock changing hands as low as $27.85 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return.
Pfizer, BioNTech Combination Flu and COVID-19 Shot Misses 1 of 2 Endpoints
Shares of Pfizer (PFE) and American depositary receipts (ADRs) of BioNTech (BNTX) dropped in intraday trading Friday following disappointing results from a late-stage study of the drugmakers' combined COVID-19 and flu vaccine in adults.
Pfizer, BioNTech COVID-19-flu combination drug meets 1 of 2 trial objectives
Pfizer Inc. PFE, -0.59% and BioNTech SE BNTX, +2.83% said Friday a Phase 3 trial of their COVID-19-influenza vaccine candidate met one of its two objectives. The companies said the candidate showed “comparable” responses against the SARS-CoV-2 virus when compared with their licensed COVID-19 vaccine, which was one objective.
